US Patent Issued to CRISPR Therapeutics on Feb. 17 for "Genetically engineered T cells with PTPN2 knockout have improved functionality and anti-tumor activity" (Massachusetts Inventor)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,553,030, issued on Feb. 17, was assigned to CRISPR Therapeutics AG (Zug, Switzerland).

"Genetically engineered T cells with PTPN2 knockout have improved functionality and anti-tumor activity" was invented by Paul Tetteh (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted Beta2M gene, and/or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof."

The patent was filed on March 8, 2022,...